Pharmaceutical Industry Outlook: Eli Lilly, Vertex, and Pfizer
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy LLY?
Source: Fool
- Eli Lilly's Market Leadership: Eli Lilly leads the chronic weight management drug market with tirzepatide, projected to generate $62 billion in annual sales by 2030, showcasing its strong capabilities in innovative drug development and market potential.
- Vertex's Unique Advantage: Vertex Pharmaceuticals holds a monopoly in cystic fibrosis drugs, targeting not only respiratory issues but also the genetic causes of the disease, with a market expected to grow at a 3% annual rate, ensuring consistent revenue and profitability.
- Pfizer's Investment Opportunity: Despite recent underperformance, Pfizer's stock trades at a low price-to-earnings ratio of 9.3, significantly below the healthcare sector average, indicating undervaluation, while the company plans to initiate over 20 phase 3 trials, potentially leading to new product launches.
- Dividend Appeal: Pfizer offers a dividend yield exceeding 6.3%, and with ongoing AI-driven cost-cutting measures, it remains an attractive option for long-term income-seeking investors.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LLY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LLY
Wall Street analysts forecast LLY stock price to rise
20 Analyst Rating
18 Buy
2 Hold
0 Sell
Strong Buy
Current: 918.050
Low
950.00
Averages
1192
High
1500
Current: 918.050
Low
950.00
Averages
1192
High
1500
About LLY
Eli Lilly and Company is a medicine company, which discovers, develops, manufactures, markets, and sells pharmaceutical products worldwide. Its cardiometabolic health products include Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound; VERVE-102; VERVE-201, and VERVE-301. Its oncology products include Cyramza, Erbitux, Tyvyt, and Verzenio. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. The Company is also engaged in radiopharmaceutical discovery, development, and manufacturing efforts, and clinical and pre-clinical radioligand therapies in development for the treatment of cancer. It is also developing an oral small molecule inhibitor of a4b7 integrin for inflammatory bowel disease (IBD). It is evaluating its novel gene therapy candidate, ixoberogene soroparvovec.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Eli Lilly Reports Positive Results for Retatrutide in Type 2 Diabetes Trial
- Clinical Trial Results: In the TRANSCEND-T2D-1 trial, participants using retatrutide achieved average A1C reductions of 1.7% to 2.0% over 40 weeks, demonstrating significant potential for improving glycemic control in diabetes patients, which could transform treatment protocols.
- Weight Loss Impact: Participants on the 12 mg dose lost an average of 36.6 lbs (approximately 16.8%), with this sustained weight loss trend indicating retatrutide's effectiveness in weight management, potentially attracting more patients to clinical trials.
- Safety Assessment: While some adverse events were reported, such as nausea (up to 26.5%) and diarrhea (up to 26.3%), these primarily occurred during dose escalation and were mostly mild, suggesting that the drug's safety profile remains within acceptable limits.
- Future Outlook: Detailed results from TRANSCEND-T2D-1 will be presented at the American Diabetes Association Scientific Sessions in June, and Eli Lilly plans to release more clinical trial results on retatrutide over the next year, further validating its therapeutic potential in diabetes treatment.
See More
UK to Reassess Alzheimer’s Drugs Exclusion from NHS
- Drug Use Reevaluation: The UK's National Institute for Health and Care Excellence (NICE) will reassess its decision to exclude two Alzheimer’s drugs from Eli Lilly (LLY) and Biogen (BIIB)/Eisai (ESALF), highlighting the importance of treatment options for patients.
- Regulatory Approval Context: Following the Medicines and Healthcare Products Regulatory Agency (MHRA) approval of these anti-amyloid drugs, NICE determined in 2024 not to include them in the National Health Service (NHS), prompting successful appeals from the manufacturers.
- Future Assessment Focus: NICE is set to revisit its final draft guidance in 2025, targeting the drugs' impact on the quality of life for Alzheimer's caregivers and the estimated costs of intravenous administration within NHS England, demonstrating a commitment to patient and family welfare.
- Positive Industry Response: Both Lilly and Eisai welcomed NICE's decision, viewing it as a significant moment in the fight against Alzheimer’s disease, indicating the industry's commitment to improving patient quality of life.
See More
Three Drugmakers with Strong Market Potential
- Eli Lilly's Market Leadership: Eli Lilly is poised to dominate the chronic weight management market with its drug tirzepatide, projected to generate $62 billion in annual sales by 2030, establishing it as the world's best-selling medicine and showcasing its competitive strength in a rapidly growing sector.
- Vertex Pharmaceuticals' Unique Position: Vertex Pharmaceuticals holds a monopoly in cystic fibrosis drugs, targeting the genetic causes of the disease, with a projected 3% annual growth rate in the patient population from 2020 to 2025, ensuring consistent revenue and earnings for the company.
- Pfizer's Potential Rebound: Despite recent underperformance, Pfizer's stock trades at a low 9.3 times forward earnings compared to the healthcare sector's average of 17.4, and the company plans to initiate over 20 phase 3 trials, which could lead to new product launches and improved financial results.
- Innovation and Investment Synergy: Eli Lilly's focus extends beyond weight loss, as it develops or licenses new medicines across various fields, demonstrating strong innovative capabilities and financial performance, making it an attractive long-term investment option.
See More
Pharmaceutical Industry Outlook: Eli Lilly, Vertex, and Pfizer
- Eli Lilly's Market Leadership: Eli Lilly leads the chronic weight management drug market with tirzepatide, projected to generate $62 billion in annual sales by 2030, showcasing its strong capabilities in innovative drug development and market potential.
- Vertex's Unique Advantage: Vertex Pharmaceuticals holds a monopoly in cystic fibrosis drugs, targeting not only respiratory issues but also the genetic causes of the disease, with a market expected to grow at a 3% annual rate, ensuring consistent revenue and profitability.
- Pfizer's Investment Opportunity: Despite recent underperformance, Pfizer's stock trades at a low price-to-earnings ratio of 9.3, significantly below the healthcare sector average, indicating undervaluation, while the company plans to initiate over 20 phase 3 trials, potentially leading to new product launches.
- Dividend Appeal: Pfizer offers a dividend yield exceeding 6.3%, and with ongoing AI-driven cost-cutting measures, it remains an attractive option for long-term income-seeking investors.
See More
ImmunityBio's Anktiva Gains New Approvals and Momentum
- Therapy Expansion: ImmunityBio's Anktiva has been included in the NCCN guidelines as a recommended option for patients with papillary bladder cancer unresponsive to BCG, thereby expanding the potential patient population, although formal FDA approval is still pending.
- Clinical Data Support: Recent clinical data indicates that 58.2% of patients remained cancer-free at 12 months, while over 80% avoided bladder removal surgery, highlighting the therapy's efficacy and significance in treatment.
- International Market Push: Anktiva has received approvals in markets like Saudi Arabia and plans to expand distribution across the Middle East and North Africa, showcasing ImmunityBio's strategic positioning and market expansion capabilities globally.
- Stock Market Reaction: IBRX shares have risen over 5% this week, breaking a two-week losing streak, reflecting positive market sentiment following Anktiva's inclusion in Macau's drug list and the NCCN guideline expansion.
See More
Investment Outlook for Eli Lilly and Vertex Pharmaceuticals
- Market Leadership of Eli Lilly: Eli Lilly's weight-loss drug tirzepatide (Zepbound) has become the world's best-selling drug, with several new weight-loss products expected to launch in the next two years, further solidifying its leadership in the rapidly growing market.
- Investment in Innovation Engine: Eli Lilly is also introducing new drugs Kisunla and Ebglyss for Alzheimer's and eczema, respectively, which, while not primary growth drivers, will help diversify its product lineup and enhance market competitiveness.
- Vertex's Diversification Strategy: Vertex Pharmaceuticals achieves strong sales through its cystic fibrosis treatments and has recently reported strong phase 3 results for povetacicept, a treatment for IgA nephropathy, indicating its potential expansion into kidney disease.
- Future Growth Potential: While Vertex's core business will continue to drive growth, new drug approvals will enable the company to move beyond cystic fibrosis by the late 2030s, highlighting its strategic significance for long-term growth.
See More
Eli Lilly Reports Positive Results for Retatrutide in Type 2 Diabetes Trial
- Clinical Trial Results: In the TRANSCEND-T2D-1 trial, participants using retatrutide achieved average A1C reductions of 1.7% to 2.0% over 40 weeks, demonstrating significant potential for improving glycemic control in diabetes patients, which could transform treatment protocols.
- Weight Loss Impact: Participants on the 12 mg dose lost an average of 36.6 lbs (approximately 16.8%), with this sustained weight loss trend indicating retatrutide's effectiveness in weight management, potentially attracting more patients to clinical trials.
- Safety Assessment: While some adverse events were reported, such as nausea (up to 26.5%) and diarrhea (up to 26.3%), these primarily occurred during dose escalation and were mostly mild, suggesting that the drug's safety profile remains within acceptable limits.
- Future Outlook: Detailed results from TRANSCEND-T2D-1 will be presented at the American Diabetes Association Scientific Sessions in June, and Eli Lilly plans to release more clinical trial results on retatrutide over the next year, further validating its therapeutic potential in diabetes treatment.
See More
UK to Reassess Alzheimer’s Drugs Exclusion from NHS
- Drug Use Reevaluation: The UK's National Institute for Health and Care Excellence (NICE) will reassess its decision to exclude two Alzheimer’s drugs from Eli Lilly (LLY) and Biogen (BIIB)/Eisai (ESALF), highlighting the importance of treatment options for patients.
- Regulatory Approval Context: Following the Medicines and Healthcare Products Regulatory Agency (MHRA) approval of these anti-amyloid drugs, NICE determined in 2024 not to include them in the National Health Service (NHS), prompting successful appeals from the manufacturers.
- Future Assessment Focus: NICE is set to revisit its final draft guidance in 2025, targeting the drugs' impact on the quality of life for Alzheimer's caregivers and the estimated costs of intravenous administration within NHS England, demonstrating a commitment to patient and family welfare.
- Positive Industry Response: Both Lilly and Eisai welcomed NICE's decision, viewing it as a significant moment in the fight against Alzheimer’s disease, indicating the industry's commitment to improving patient quality of life.
See More
Three Drugmakers with Strong Market Potential
- Eli Lilly's Market Leadership: Eli Lilly is poised to dominate the chronic weight management market with its drug tirzepatide, projected to generate $62 billion in annual sales by 2030, establishing it as the world's best-selling medicine and showcasing its competitive strength in a rapidly growing sector.
- Vertex Pharmaceuticals' Unique Position: Vertex Pharmaceuticals holds a monopoly in cystic fibrosis drugs, targeting the genetic causes of the disease, with a projected 3% annual growth rate in the patient population from 2020 to 2025, ensuring consistent revenue and earnings for the company.
- Pfizer's Potential Rebound: Despite recent underperformance, Pfizer's stock trades at a low 9.3 times forward earnings compared to the healthcare sector's average of 17.4, and the company plans to initiate over 20 phase 3 trials, which could lead to new product launches and improved financial results.
- Innovation and Investment Synergy: Eli Lilly's focus extends beyond weight loss, as it develops or licenses new medicines across various fields, demonstrating strong innovative capabilities and financial performance, making it an attractive long-term investment option.
See More
Pharmaceutical Industry Outlook: Eli Lilly, Vertex, and Pfizer
- Eli Lilly's Market Leadership: Eli Lilly leads the chronic weight management drug market with tirzepatide, projected to generate $62 billion in annual sales by 2030, showcasing its strong capabilities in innovative drug development and market potential.
- Vertex's Unique Advantage: Vertex Pharmaceuticals holds a monopoly in cystic fibrosis drugs, targeting not only respiratory issues but also the genetic causes of the disease, with a market expected to grow at a 3% annual rate, ensuring consistent revenue and profitability.
- Pfizer's Investment Opportunity: Despite recent underperformance, Pfizer's stock trades at a low price-to-earnings ratio of 9.3, significantly below the healthcare sector average, indicating undervaluation, while the company plans to initiate over 20 phase 3 trials, potentially leading to new product launches.
- Dividend Appeal: Pfizer offers a dividend yield exceeding 6.3%, and with ongoing AI-driven cost-cutting measures, it remains an attractive option for long-term income-seeking investors.
See More
ImmunityBio's Anktiva Gains New Approvals and Momentum
- Therapy Expansion: ImmunityBio's Anktiva has been included in the NCCN guidelines as a recommended option for patients with papillary bladder cancer unresponsive to BCG, thereby expanding the potential patient population, although formal FDA approval is still pending.
- Clinical Data Support: Recent clinical data indicates that 58.2% of patients remained cancer-free at 12 months, while over 80% avoided bladder removal surgery, highlighting the therapy's efficacy and significance in treatment.
- International Market Push: Anktiva has received approvals in markets like Saudi Arabia and plans to expand distribution across the Middle East and North Africa, showcasing ImmunityBio's strategic positioning and market expansion capabilities globally.
- Stock Market Reaction: IBRX shares have risen over 5% this week, breaking a two-week losing streak, reflecting positive market sentiment following Anktiva's inclusion in Macau's drug list and the NCCN guideline expansion.
See More
Investment Outlook for Eli Lilly and Vertex Pharmaceuticals
- Market Leadership of Eli Lilly: Eli Lilly's weight-loss drug tirzepatide (Zepbound) has become the world's best-selling drug, with several new weight-loss products expected to launch in the next two years, further solidifying its leadership in the rapidly growing market.
- Investment in Innovation Engine: Eli Lilly is also introducing new drugs Kisunla and Ebglyss for Alzheimer's and eczema, respectively, which, while not primary growth drivers, will help diversify its product lineup and enhance market competitiveness.
- Vertex's Diversification Strategy: Vertex Pharmaceuticals achieves strong sales through its cystic fibrosis treatments and has recently reported strong phase 3 results for povetacicept, a treatment for IgA nephropathy, indicating its potential expansion into kidney disease.
- Future Growth Potential: While Vertex's core business will continue to drive growth, new drug approvals will enable the company to move beyond cystic fibrosis by the late 2030s, highlighting its strategic significance for long-term growth.
See More
